WO2007051119A8 - Methods and compositions of parp inhibitors as potentiators in cancer therapy - Google Patents

Methods and compositions of parp inhibitors as potentiators in cancer therapy

Info

Publication number
WO2007051119A8
WO2007051119A8 PCT/US2006/060219 US2006060219W WO2007051119A8 WO 2007051119 A8 WO2007051119 A8 WO 2007051119A8 US 2006060219 W US2006060219 W US 2006060219W WO 2007051119 A8 WO2007051119 A8 WO 2007051119A8
Authority
WO
WIPO (PCT)
Prior art keywords
potentiators
compositions
methods
cancer therapy
parp inhibitors
Prior art date
Application number
PCT/US2006/060219
Other languages
French (fr)
Other versions
WO2007051119A1 (en
Inventor
Dana Victor Ferraris
Jia-He Li
Vincent Kalish
Jie Zhang
Original Assignee
Mgi Gp Inc
Dana Victor Ferraris
Jia-He Li
Vincent Kalish
Jie Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mgi Gp Inc, Dana Victor Ferraris, Jia-He Li, Vincent Kalish, Jie Zhang filed Critical Mgi Gp Inc
Publication of WO2007051119A1 publication Critical patent/WO2007051119A1/en
Publication of WO2007051119A8 publication Critical patent/WO2007051119A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present disclosure relates generally to a series of compounds which are derivatives of tricyclic compounds which inhibit poly (ADP-ribose) polymerase (PARP) and their use in the potentiation of cancer therapies. The disclosure relates more particularly to uses of azaphenanthridone compounds to chemosensitize cancers to the cytotoxic effects of chemopharmaceutical agents.
PCT/US2006/060219 2005-10-26 2006-10-25 Methods and compositions of parp inhibitors as potentiators in cancer therapy WO2007051119A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73001705P 2005-10-26 2005-10-26
US60/730,017 2005-10-26

Publications (2)

Publication Number Publication Date
WO2007051119A1 WO2007051119A1 (en) 2007-05-03
WO2007051119A8 true WO2007051119A8 (en) 2007-11-22

Family

ID=37806858

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/060219 WO2007051119A1 (en) 2005-10-26 2006-10-25 Methods and compositions of parp inhibitors as potentiators in cancer therapy

Country Status (1)

Country Link
WO (1) WO2007051119A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5399905B2 (en) * 2006-09-01 2014-01-29 センワ バイオサイエンシズ インコーポレイテッド Serine-threonine protein kinase and PARP regulator
WO2010082813A1 (en) * 2009-01-13 2010-07-22 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Method of treating cancer
US8541417B2 (en) * 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
CN112279810B (en) * 2020-12-25 2021-05-18 北京华氏开元医药科技有限公司 6-oxo-5, 6-dihydrophenanthridine-4-formamide compound, preparation method, pharmaceutical composition and application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1339402B1 (en) * 2000-12-01 2010-08-25 Eisai Inc. Azaphenanthridone derivatives and their use as parp inhibitors
US7072771B2 (en) * 2001-06-07 2006-07-04 University Of Kentucky Research Foundation Selective PARP-1 targeting for designing chemo/radio sensitizing agents
BRPI0515567A (en) * 2004-09-22 2008-07-29 Pfizer therapeutic combinations comprising poly (adp-ribose) polymerase inhibitor

Also Published As

Publication number Publication date
WO2007051119A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
WO2005110477A3 (en) Combination therapies for cancer and proliferative angiopathies
WO2006113470A3 (en) Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2010027423A3 (en) Compositions of pd-1 antagonists and methods of use
WO2007011962A3 (en) Treatment of cancer
WO2008030883A3 (en) Treatment of cancer
MX2010006154A (en) Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors.
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2006113703A3 (en) Carboline derivatives useful in the treatment of cancer
IL199151A (en) Pyrimidine derivatives, pharmaceutical compositions comprising them, their use in the treatment of cancer and kits comprising them
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2007002931A3 (en) Phosphoramidate alkylator prodrugs
WO2006012642A3 (en) Pyrrole derivatives as pharmaceutical agents
MX2009006706A (en) Bicyclic heterocyclic compounds as fgfr inhibitors.
WO2006089150A3 (en) Antiangiogenic agents with aldesleukin
WO2007081710A3 (en) Treatment modalities for autoimmune diseases
WO2004087713A8 (en) Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
JO2721B1 (en) Artemisinin Derivative Dimers, Their preparation and their therapeutic application
WO2008002460A3 (en) Orally available light-independent antineoplastic compounds
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
GB2453011B (en) Antifolate agent compositions in the treatment of cancer
WO2005086971A3 (en) Anti-metastatic ability of mibefradil and gadolinium
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2007051119A8 (en) Methods and compositions of parp inhibitors as potentiators in cancer therapy
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
WO2007120726A3 (en) Compositions and methods related to rad51 inactivation in the treatment of neoplastic diseases, and especially cml

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06839537

Country of ref document: EP

Kind code of ref document: A1